Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4823-4832

  Tamura, Nozomi ^a   Hirano, Kumi ^a   Kishino, Kaori ^a   Hashimoto, Ken ^a   Amano, Osamu ^a   Shimada, Jun ^a   Sakagami, Hiroshi ^a  

^a MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

Author keywords

Apoptosis; Autophagy; HSC 2; HSC 4 cells; Irinotecan; Oral sqamous cell carcinoma; SN 38; Topoisomerase inhibitors

Indexed keywords

3 METHYLADENINE; BAFILOMYCIN A1; CAMPTOTHECIN; CASPASE 3; CASPASE INHIBITOR; ETOPOSIDE; FIRTECAN; IRINOTECAN; TENIPOSIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL; CANCER CELL CULTURE; CELL ASSAY; CELL DEATH; CELL STRUCTURE; COMPARATIVE TOXICOLOGY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; EPITHELIUM CELL; FIBROBLAST; GLIOBLASTOMA; GOLGI COMPLEX; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; MOUTH SQUAMOUS CELL CARCINOMA; MYELOID LEUKEMIA; PERIODONTAL LIGAMENT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA FRAGMENTATION; HL-60 CELLS; HUMANS; IN SITU NICK-END LABELING; MOUTH NEOPLASMS; TOPOISOMERASE INHIBITORS;

EID: 84872669031     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Chabner BA, Amrein PC, Druker B, Michaelson MD, Mitsiades CS, Goss PE, Ryan DP, Ramachandra S, Richardson PG, Supko JG and Wilson WH: Chapter 51: Chemotherapy of neoplastic diseases. In : Goodman & Gilman's The Pharmacological Basis of Therapeutics, eleventh edition. Brunton LL, Lazo JS and Parker KL (eds.). New York, McGraw Hill, pp. 1315-1403, 2006.
2. Hanley K, Komuves LG, Bass NM, He SS, Jiang Y, Crumrine D, Appel R, Friedman M, Bettencourt J, Min K, Elias PM, Williams ML and Feingold KR: Fetal epidermal differentiation and barrier development in vivo is accelerated by nuclear hormone receptor activators. J Invest Dermatol 113: 788-795, 1999.
3. Gupta M, Fujimori A and Pommier Y: Eukaryotic DNA topoisomerase I. Biochem Biophys Acta 1262: 1-14, 1995.
4. Husain I, Mohler JL, Seigler HF and Besterman JM: Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54: 539-546, 1994.
5. Hsiang Y, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989.
6. Takeba Y, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y and Kobayashi S: Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J Pharmacol Sci 104: 232-242, 2007.
7. Takeba Y, Sekine S, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y, Nakano H, Asakura T, Ohtsubo T and Kobayashi S: Irinotecan-induced apoptosis is inhibited by increased Pglycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol Pharm Bull 30: 1400-1406, 2007.
8. de Gramont A, Figer A, Seymour M, Homerin M,Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
9. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Lveson T, Carmichael J, Alaki M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355: 1041-1047, 2000.
10. Broker LE, Kruyt FA and Giaccone G: Cell death independent of caspase: A review. Clin. Cancer Res 11: 3155-3162, 2005.
11. Derbnath J, Baehrecke EH and Kroemer G: Does autophagy contribute to cell death? Autophagy 1: 66-74, 2005.
12. Kantoh K, Ono M, Nakamura Y, Nakamura Y, Hashimoto K, Sakagami H and Wakabayashi H: Hormetic and anti-radiation effects of tropolone-related compounds. In Vivo 24: 843-852, 2010.
13. Kishino K, Hashimoto K, Amano O, Kochi M and Sakagami H: Tumor-specific cytotoxicity and type of cell death induced by sodium 5,6-benzylidene-L- ascorbate. Anticancer Res 28: 2577-2584, 2008.
14. Yanagisawa-Shiota F, Sakagami H, Kuribayashi N, Iida M, Sakagami T and Takeda M: Endonuclease activity and induction of DNA fragmentation in human myelogenous leukemic cell lines. Anticancer Res 15: 259-266, 1995.
15. Otsuki S, Sugiyama K, Amano O, Yasui T and Sakagami H: Negative regulation of NaF-induced apoptosis by Bad-CAII complex. Toxicology 287: 131-136, 2011.
16. Ideo A, Hashimoto K, Shimada J, Kawase M and Sakagami H: Type of cell death induced by á-trifluoromethyl acyloins in oralsquamous cell carcinoma. Anticancer Res 29: 175-182, 2009.
17. Wu Y-T, Tan H-L, Shui G, Bauvy C, Huang Q, Wenk MR, Ong C-N, Codogno P and Shen H-M: Dual role of 3-methyladenine in modulation of autophagy via different terporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 285: 10850-10861, 2010.
18. Wu YC, Wu WK, Li Y, Yu L, Li ZJ, Wong CC, Li HT, Sung JJ and Cho CH: Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. Biochem Biophys Res Commun 382: 451-456, 2009.
19. Fujisawa S, Atsumi T, Kadoma Y and Sakagami H: Antioxidant and prooxidant action of eugenol-related compounds and their cytotoxicity. Forum "Phenolic compounds: Free radical mechanisms of toxicity, and protection". Toxicology 177: 39-54, 2002.
20. Ishihara M, Yokote Y and Sakagami H: Quantitative structure-cytotoxicity relationship analysis of coumarin and its derivatives by semiempirical molecular-orbital method. Anticancer Res 26: 2883-2886, 2006.
21. Robey RW, Polgar O, Deeken J, To KW and Bates SE: ABCG2: Determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26: 39-57, 2007.
22. Bhattacharya A, Tóth K, Durrani F A, Cao S, Slocum H K, Chintala S and Rustum Y M: Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts. Neoplasia 10: 857-865, 2008.
23. Han JY, Lee DH, Lee SY, Park CG, Kim HY, Lee HG, Lee JJ, Kim HT and Lee JS: Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced non-small cell lung carcinoma. Cancer 104: 2759-2765, 2005
24. Pectasides D, Visvikis A, Kouloubinis A, Glotsos J, Bountouroglou N, Karvounis N, Ziras N and Athanassiou A: Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small cell lung cancer: A phase II study. Eur J Cancer 38: 1194-2000, 2002.
25. Dunn WA: Autophagy and related mechanisms of lysosomemediated protein degradation. Trends Cell Biol 4: 139-143, 1994.
26. Jin S: Autophagy, mitochondria quality control, and oncogenesis. Autophagy 2: 80-84, 2006.